Literature DB >> 3066994

Preliminary evaluation of the Abbott TDx for benzoylecgonine and opiate screening in whole blood.

C E McCord1, J R McCutcheon.   

Abstract

A method for the detection of benzoylecgonine (cocaine metabolite) and opiates in whole blood is described. This method employs the Abbott TDx fluorescence polarization immunoassay technique, which was designed for urine analysis. Drug-free whole blood was spiked with varying concentrations of benzoylecgonine, morphine, and codeine. Samples were prepared for analysis by adding 300 microL of 10% trichloroacetic acid to 300 microL of blood. Specimens were vortexed and centrifuged with 50 microL of supernatant required per assay. Precision studies of six replicate samples spiked with benzoylecgonine at 0.5 mg/L gave a within-run CV of 4.7% and a between-run CV of 4.7% with a detection limit of 0.1 mg/L. Within-run CVs for morphine at 0.5 mg/L and 0.1 mg/L were 1.7% and 7.9% respectively. The detection limits for morphine and codeine were 0.05 mg/L. Correlation coefficients for spiked whole blood calibration curves of benzoylecgonine, morphine, and codeine were 0.984, 0.999, and 0.997 respectively. This preliminary evaluation demonstrates a potential application of the TDx fluorescence polarization immunoassay technique to the analysis of drugs in whole blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3066994     DOI: 10.1093/jat/12.5.295

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  2 in total

1.  The screening for common drugs of abuse in whole blood by means of EMIT-ETS and FPIA-ADx urine immunoassays.

Authors:  R D Maier; M Erkens; H Hoenen; M Bogusz
Journal:  Int J Legal Med       Date:  1992       Impact factor: 2.686

2.  Fluorometric determination of morphine via its effect on the quenching of fluorescein by gold nanoparticles through a surface energy transfer process.

Authors:  John Nebu; J S Anjali Devi; R S Aparna; B Aswathy; A O Aswathy; George Sony
Journal:  Mikrochim Acta       Date:  2018-11-06       Impact factor: 5.833

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.